echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The melanoma "first-line treatment drug" Endo finally fell off the altar.

    The melanoma "first-line treatment drug" Endo finally fell off the altar.

    • Last Update: 2020-10-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, many melanoma patients come to Beijing Cancer Hospital for treatment, are asked to use a drug called Endo, and are told it is the recommended treatment for melanoma.
    many patients with basic medical knowledge have expressed doubts, Endo is only approved by the China Drug Administration for the treatment of lung cancer, how can it be used for the treatment of melanoma? The reason for this is to start from Endo's previous life.
    American scientist Judah Folkman was one of the first discoverers of angiostatin and endostatin.
    many of today's anti-angiogenesic targeted drugs have been developed successfully by his students.
    in 1991, he discovered endostatin, and began developing it through Thendremed, the company he founded.
    , however, in the second phase of clinical trials sponsored by international pharmaceutical giant Meimei, the stability and effectiveness of the drug were found to be poor, and preparation difficulties, only to stop clinical trials.
    2004, The Company announced the suspension of research and development.
    In 1999, Luo Yongzhang, a Chinese scholar, returned home from the United States, bringing back endostatin, which had been "abandoned", adding several amino acid modification Endostatins and renaming it ENDOSTAR, which was repackaged and then listed in China in 2006 for the treatment of advanced non-small cell lung cancer (including squamous cancer).
    2008, Nanjing Synth Pharmaceuticals acquired Endo.
    2009, Synthesic Pharmaceuticals, in conjunction with the team of Guo Jun for melanoma at Beijing Cancer Hospital, conducted the second phase of clinical trials of Endo-combined chemotherapy.
    the results: the objective response rate was only 4.5 months, and the medium lifetime (OS) was only 8 months.
    patients with advanced melanoma also have a lifesaly period of 6-8 months without any medication.
    this experiment only shows that endeeen's efficacy is the same as that of a common placebo.
    2012, Synth Pharmaceuticals again wanted to try a clinical trial of Endo-dakabazine.
    the results of the trial, initiated and led by Professor Guo Jun of Beijing Cancer Hospital, had a PFS of 4.5 months and a medium survival of 12 months.
    is the first FDA-approved drug to treat melanoma in the United States, with a medium survival of up to eight months.
    the experimental data clearly show that the efficacy of endeen is poor.
    's point in using Endo for melanoma treatment! By 2020, the China Drug Administration had approved a variety of targeted and immunologic drugs for the treatment of melanoma.
    but some doctors still use Endo as a treatment and recommend it to melanoma patients.
    's why? In August 2019, documents issued by the Beijing Municipal Health and Health Commission revealed the truth, which showed that the pharmaceutical industry had seven drugs, bribed doctors through medical representatives, gave doctors high rebates, and increased drug sales.
    the name of The Goodyear is in sight, with rebates of up to 25 per cent.
    a total of 21 hospitals involved, the Beijing Municipal Health and Planning Commission asked to investigate the matter thoroughly.
    Endo was approved by the Chinese Drug Administration as a lung cancer treatment drug, but without sufficient theoretical research and scientific evidence, but still as a recommended drug for melanoma patients, which is appalling.
    these so-called therapies, miss the best treatment time for patients, to these melanoma patients worse! Only doctors who respect science, respect patients, and think of patients with the first heart of healing are doctors with conscience!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.